e-ISSN: Pending

Browse the failure-mode index

286 real negative results, null findings, and replication failures in Medicine · Replication Failure. Search the index →

WASTE indexes published research — it does not host or republish full papers. Each entry is a metadata record compiled from open scholarly databases; the abstract is shown in full only where the paper is openly licensed, otherwise a short excerpt under fair use. Classifications are automated and approximate.

Replication FailureMedicine

A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT).

Anthony T.�C. Chan, Edwin P. Hui, Roger K.C. Ngan et al. · 2017 · Journal of Clinical Oncology

6002 Background: The benefit of adjuvant CT in NPC is unclear. Post-RT EBV DNA predicts poor survival and may be a biomarker of subclinical residual disease. We conducted a biomarker driven RCT using post-RT EBV DNA to select high risk NPC…

View details →
Replication FailureOpen accessMedicine

The Effect of Genetic Variation on the Placental Transcriptome in Humans

Triin Kikas, Kristiina Rull, Robin N. Beaumont et al. · 2019 · Frontiers in Genetics

= 6830) did not replicate these findings. In summary, the study emphasizes the role of genetic variation in driving the transcriptome profile of the human placenta and the importance to explore further its functional implications.

View details →
Replication FailureOpen accessMedicine

Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab versus Transarterial Chemoembolization Alone in Intermediate‐stage Hepatocellular Carcinoma: A Multicenter Retrospective Study

Yitao Zheng, Yan‐Jun Xiang, Hongqi Shi et al. · 2024 · Journal of Hepatocellular Carcinoma

Purpose: Combining transarterial chemoembolization (TACE) with systemic therapy has shown significant efficacy for intermediate-stage hepatocellular carcinoma (HCC) patients. This study aimed to validate the therapeutic efficacy of TACE…

View details →
Replication FailureOpen accessMedicine

Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double‐blind, placebo‐controlled phase 3 studies and their open‐label extension

Nichola Cooper, James B. Bussel, Maciej Kaźmierczak et al. · 2024 · British Journal of Haematology

Summary Primary immune thrombocytopenia (ITP) is an antiplatelet‐antibody‐mediated disorder with accelerated platelet clearance and decreased platelet production. Rozanolixizumab, a monoclonal IgG4 anti‐FcRn antibody, blocks IgG recycling and decreases IgG levels. We report efficacy and safety of rozanolixizumab in adults with persistent/chronic ITP in 24‐week phase 3 studies (TP0003; TP0006), and their 52‐week open‐label extension (OLE). Primary end‐point was durable clinically meaningful platelet response (DCMPR) of ≥50 × 10 9 /L for 8/12 weeks during Weeks 13–25 in the double‐blind studies.

View details →
Replication FailureOpen accessMedicine

Long-Term Outcomes of Left Bundle-Branch Pacing vs Biventricular Pacing in Heart Failure

Xueying Chen, Xi Liu, Ruogu Li et al. · 2026 · JAMA Cardiology

Importance: Left bundle-branch pacing (LBBP) has been proposed as an alternative to biventricular pacing (BiVP) for patients with heart failure with left bundle-branch block (LBBB). However, robust clinical evidence from randomized clinical trials is lacking. Objective: To evaluate the long-term clinical outcomes of LBBP and BiVP. Design, Setting, and Participants: This multicenter, prospective, randomized clinical trial enrolled 200 patients at 6 centers in China with a left ventricular ejection fraction (LVEF) of 35% or less and LBBB from October 2020 to March 2022. This study was took place

View details →
Replication FailureOpen accessMedicine

A Smartphone App Self-Management Program for Chronic Obstructive Pulmonary Disease: Randomized Controlled Trial of Clinical Outcomes

Lisa H. Glynn, E Moloney, Stephen Lane et al. · 2025 · JMIR mhealth and uhealth

BACKGROUND: Chronic obstructive pulmonary disease (COPD) negatively impacts clinical health outcomes, resulting in frequent exacerbations, increased hospitalizations, reduced physical activity, deteriorated quality of life, and diminished self-efficacy. Previous studies demonstrated that a self-management program tailored for adults with COPD improves self-management decisions, resulting in a positive effect on clinical health outcomes. Limitations of these studies include issues regarding heterogeneity among interventions used, patient population characteristics, outcome measures, and longitu

View details →
Replication FailureOpen accessMedicine

Tavapadon as Adjunctive Treatment for Parkinson Disease

Hubert H. Fernandez, S. H. Isaacson, Robert A. Hauser et al. · 2026 · JAMA Neurology

Importance: Development of motor fluctuations is common in people with Parkinson disease (PD) treated with oral levodopa, and currently available dopamine (D) agonists adjunctive to levodopa offer additional motor control but may increase…

View details →
Replication FailureOpen accessMedicine

Genome-wide association study of idiopathic pulmonary fibrosis susceptibility using clinically curated European ancestry datasets

Daniel Chin, Tamara Hernández-Beeftink, Lauren J. Donoghue et al. · 2026 · European Respiratory Journal

ABSTRACT Background Idiopathic pulmonary fibrosis (IPF) is a rare, incurable lung disease with a median survival of 3-5 years after diagnosis. Treatment options are limited. Genetic association studies can identify new genes involved in disease that might represent potential new drug targets, and it has been shown that drug targets with support from genetic studies are more likely to be successful in clinical development. Previous genome-wide association studies (GWAS) of IPF susceptibility have identified more than 20 signals implicating genes involved in multiple mechanisms, including telome

View details →
Replication FailureOpen accessMedicine

CAR T-Cell Targeting of Macrophage Colony-Stimulating Factor Receptor

Daniela Achkova, Richard Beatson, John Maher · 2022 · Cells

Macrophage colony-stimulating factor receptor (M-CSFR) is found in cells of the mononuclear phagocyte lineage and is aberrantly expressed in a range of tumours, in addition to tumour-associated macrophages. Consequently, a variety of cancer therapies directed against M-CSFR are under development. We set out to engineer chimeric antigen receptors (CARs) that employ the natural ligands of this receptor, namely M-CSF or interleukin (IL)-34, to achieve specificity for M-CSFR-expressing target cells. Both M-CSF and IL-34 bind to overlapping regions of M-CSFR, although affinity of IL-34 is significa

View details →
Replication FailureOpen accessMedicine

Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial

Kang Wang, Jinkai Feng, Hongming Yu et al. · 2025 · Signal Transduction and Targeted Therapy

Transarterial chemoembolization (TACE) is the standard treatment for intermediate-stage hepatocellular carcinoma (HCC), yet its efficacy as a standalone therapy remains suboptimal. This phase 2 trial (ChiCTR2100049829) evaluated the feasibility and safety of TACE combined with atezolizumab and bevacizumab in patients with intermediate-stage HCC. Participants received TACE followed by atezolizumab and bevacizumab until disease progression, unacceptable toxicity, or death. The primary endpoint was objective response rate (ORR) assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1

View details →
Replication FailureOpen accessMedicine

Randomized Sham-controlled Trial of Targeted Lung Denervation in Patients with Chronic Obstructive Pulmonary Disease (AIRFLOW-3)

Pallav L. Shah, Dirk‐Jan Slebos, Richard Sue et al. · 2025 · American Journal of Respiratory and Critical Care Medicine

Abstract Rationale AIRFLOW-3 was a 1:1 randomized, double-blind, sham-controlled trial of the D’Nerva targeted lung denervation (TLD) system in patients with chronic obstructive pulmonary disease (COPD). Objective To evaluate the impact of…

View details →
Replication FailureOpen accessMedicine

Randomized trial investigating the utility of a liver tissue transcriptional biomarker in identifying adult liver transplant recipients not requiring maintenance immunosuppression

Julien Vionnet, Jorge P. Torres-Yaguana, Rosa Miquel et al. · 2024 · American Journal of Transplantation

The maintenance of stable allograft status in the absence of immunosuppression (IS), known as operational tolerance, can be achieved in a small proportion of liver transplant recipients, but we lack reliable tools to predict its spontaneous development. We conducted a prospective, multicenter, biomarker-strategy design, IS withdrawal clinical trial to determine the utility of a predictive biomarker of operational tolerance. The biomarker test, originally identified in a patient cohort with high operational tolerance prevalence, consisted of a 5-gene transcriptional signature measured in liver

View details →
Replication FailureOpen accessMedicine

A Ketogenic Diet for Treatment-Resistant Depression

Min Gao, Megan Kirk, Heather Knight et al. · 2026 · JAMA Psychiatry

Importance: Preclinical evidence and case reports suggest potential therapeutic benefits of ketogenic diets (KDs) in the treatment of depression, but evidence from well-controlled randomized clinical trials (RCTs) is lacking. Objective: To assess the efficacy of a KD compared with a control diet in adults with treatment-resistant depression (TRD). Design, Setting, and Participants: This RCT was conducted between February 22 and June 15, 2024. Participants aged 18 to 65 years with TRD and a score of 15 or greater on the 9-item Patient Health Questionnaire (PHQ-9) from across the UK were include

View details →
Replication FailureOpen accessMedicine

Targeting the sirtuin 6–NF-κB p65 axis by 6-hydroxyhyoscyamine hydrobromide: a deacetylation-driven new therapy for diabetic wounds

Junren Chen, Siqi Qin, Ziwei Xing et al. · 2026 · Cellular & Molecular Biology Letters

BACKGROUND: Diabetic wounds are a debilitating complication of diabetes mellitus with a high rate of amputation and mortality. 6-Hydroxyhyoscyamine hydrobromide (6-HH) is a belladonna alkaloid with smooth-muscle-relaxing and…

View details →
Replication FailureOpen accessMedicine

Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients

Christopher C. Butler, Andrew Pinto, Victoria Harris et al. · 2026 · New England Journal of Medicine

BACKGROUND: Nirmatrelvir-ritonavir has been shown to reduce progression to severe illness from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in unvaccinated high-risk outpatients. The effectiveness of nirmatrelvir-ritonavir in persons who have been vaccinated, infected naturally, or both is unclear. METHODS: In two open-label platform trials (PANORAMIC in the United Kingdom and CanTreatCOVID in Canada), we enrolled higher-risk adults (≥50 years of age or ≥18 years of age with coexisting conditions) in the community who tested positive for SARS-CoV-2 and had been unwell for 5 day

View details →
Replication FailureOpen accessMedicine

Vitamin D in Cardiovascular Medicine: From Molecular Mechanisms to Clinical Translation

Fahimeh Varzideh, Pasquale Mone, Urna Kansakar et al. · 2026 · Nutrients

Vitamin D, a fat-soluble secosteroid traditionally recognized for skeletal health, exerts pleiotropic effects on cardiovascular physiology and disease. Circulating 25-hydroxyvitamin D [25(OH)D], the principal biomarker of vitamin D status, is frequently suboptimal worldwide, particularly in older adults, individuals with darker skin pigmentation, and populations at higher latitudes. Observational studies consistently associate low 25(OH)D concentrations with increased risk of hypertension, atherosclerosis, myocardial infarction, heart failure, arrhythmias, stroke, and cardiovascular mortality.

View details →
Replication FailureOpen accessMedicine

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial

Wungki Park, Catherine O’Connor, Joanne F. Chou et al. · 2026 · Nature Medicine

Homologous recombination deficiency (HRD) arising from BRCA1or BRCA2 or PALB2 mutations confers sensitivity to platinum chemotherapy and PARP inhibition in pancreatic cancer (PC) and may enable prolonged disease control with immune checkpoint blockade (ICB). The phase 2 POLAR trial evaluated maintenance pembrolizumab plus olaparib following platinum-based chemotherapy in biomarker-stratified metastatic PC. Sixty-three participants were enrolled into three cohorts: cohort A (BRCA1/BRCA2-mutated or PALB2-mutated HRD, n = 33), cohort B (non-core HRD, n = 15) and cohort C (platinum sensitive, HRD-

View details →
Replication FailureOpen accessMedicine

Combined intravenous bolus amino acid supplementation and mobilization on early muscle loss in critically ill adults: A randomized controlled trial

Lizl Veldsman, GA Richards, D. G. Nel et al. · 2025 · Journal of Parenteral and Enteral Nutrition

BACKGROUND: Muscle wasting is a hallmark of critical illness. We evaluated the effect of amino acid supplementation and mobilization on early muscle loss in critically ill patients. METHODS: We conducted a randomized parallel-group trial…

View details →
Replication FailureOpen accessMedicine

Safety and efficacy of adjunct dexamethasone in adults with herpes simplex virus encephalitis in the UK (DexEnceph): a multicentre, observer-blind, randomised, phase 3, controlled trial

Tom Solomon, Cory Hooper, Ava Easton et al. · 2026 · The Lancet Neurology

BACKGROUND: Herpes simplex virus (HSV) encephalitis is characterised by inflammation and swelling of the brain, resulting in death or severe neurocognitive sequelae. HSV encephalitis is treated with the antiviral aciclovir but still has substantial mortality and morbidity. Adjunct corticosteroids are sometimes used, but whether they improve the outcome is unclear. We aimed to establish the safety and efficacy of adjunct corticosteroids in HSV encephalitis. METHODS: In this multicentre, observer-blind, randomised, phase 3 trial, adults with HSV encephalitis admitted to 53 hospitals in the UK we

View details →
Replication FailureOpen accessMedicine

Evaluating a Mobile Digital Therapeutic for Vasomotor and Behavioral Health Symptoms Among Women in Midlife: Randomized Controlled Trial

Jennifer Duffecy, Arfa Rehman, Scott Gorman et al. · 2025 · JMIR mhealth and uhealth

Unlabelled: Background: Perimenopausal and menopausal symptoms affect many women's well-being and quality of life. Digital technologies, especially smartphones, allow self-management interventions for menopausal symptoms, but they are understudied., Objective: We evaluated whether a novel digital care app, Caria, effectively reduced vasomotor and behavioral health symptoms of menopause., Methods: We enrolled 149 women for a 6-week randomized controlled trial (app treatment: n=112; web-based educational control: n=37). Enrolled participants had problematic vasomotor symptoms and at least one el

View details →
Replication FailureOpen accessMedicine

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial

Domenica Lorusso, Laurence Gladieff, David M O'Malley et al. · 2026 · The Lancet

BACKGROUND: Relacorilant is a selective glucocorticoid receptor antagonist that increases the sensitivity of many cancer cell types to chemotherapy. The efficacy and safety of relacorilant plus nab-paclitaxel were assessed in the phase 3 ROSELLA (GOG-3073, ENGOT-ov72, APGOT-Ov10, and LACOG-0223) trial; the combination showed significant improvement in progression-free survival among patients with platinum-resistant ovarian cancer compared with nab-paclitaxel monotherapy. Results of the final overall survival analysis are reported here. METHODS: intravenously on the aforementioned schedule). Pa

View details →
Replication FailureOpen accessMedicine

Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial

Mette Kruse Klausen, Signe Justesen, Julie Niemann Pedersen et al. · 2026 · The Lancet

BACKGROUND: Alcohol use disorder accounts for 5% of deaths worldwide annually, and there is an urgent need for new therapeutic interventions. Preclinical and initial human studies indicate that the GLP-1 receptor agonist semaglutide might reduce alcohol drinking. This study evaluated the efficacy of semaglutide once-weekly in treatment-seeking patients with alcohol use disorder and comorbid obesity. METHODS: In a 26-week, single-centre, randomised, double-blinded, placebo-controlled trial, treatment-seeking participants with moderate to severe alcohol use disorder and comorbid obesity were ass

View details →
Replication FailureOpen accessMedicine

Triple cardiovascular disease detection with an artificial intelligence-enabled stethoscope (TRICORDER) in the UK: a cluster-randomised controlled implementation trial

Mihir A Kelshiker, Patrik Bächtiger, Camille F Petri et al. · 2026 · The Lancet

BACKGROUND: Early detection of cardiovascular disease is a global public health priority. Artificial intelligence (AI)-enabled stethoscopes offer robust performance characteristics in point-of-care detection of heart failure, atrial fibrillation, and valvular heart disease (VHD). We conducted a pragmatic, cluster-randomised controlled implementation trial to determine the real-world effect and implementation challenges of AI-stethoscopes. METHODS: UK primary care practices were cluster randomised 1:1 to intervention (training and implementation in use of AI-stethoscopes in routine care) or con

View details →